

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,700,276 B2
APPLICATION NO. : 10/563503
DATED : April 20, 2010
INVENTOR(S) : Stordeur et al.


Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 4, Line 35, "nucleic add stabilising" should be changed to --nucleic acid stabilising--
Column 4, Line 42, "of step (f using" should be changed to --of step (f) using--
Column 6, Line 28, "are selected from one" should be changed to --selected from one--
Column 6, Line 29, "tetanous toxoid," should be changed to --tetanus toxoid,--
Column 7, Line 13, "the RNAlater reagent" should be changed to --the RNA later reagent--
Column 7, Line 17, NaCl alone or an" should be changed to --NaCl alone or an--
Column 8, Line 61, "I.42-43). Therefore," should be changed to --1.42-43). Therefore,--
Column 11, Line 14, "is tetanous toxoid." should be changed to --is tetanus toxoid.--
Column 18, Line 59, "directly of indirectly" should be changed to --directly or indirectly--
Column 19, Line 2, "with an identical similar" should be changed to --with an
identical/similar--
Column 19, Line 53, "the pulsed/nonpulsed cells," should be changed to
--the pulsed/non-pulsed cells,--
Column 26, Line 8, "the same individual," should be changed to --the same individuals,--
Column 26, Line 32, "tetradecyltrimethylammonium oxalate" should be changed to
--tetradecyltrimethylammonium oxalate--
Column 29, Line 21, "(dendritic cells," should be changed to --(dendritic cells,--
Column 29, Line 64, "epitope-specific CTLs" should be changed to --epitope-specific CTLs--
Column 30, Line 44, "is damaged Would" should be changed to --is damaged would--
Column 30, Line 48, "subclinical episodes of" should be changed to --sub-clinical episodes of--
Column 31, Line 15, "PureTM instrument" should be changed to -- PureTM instrument--

Signed and Sealed this

Seventh Day of September, 2010



David J. Kappos
Director of the United States Patent and Trademark Office

Column 31, Line 45, “of the PAXgene™**0** tube’s” should be changed to --of the PAXgene™ tube’s--

Column 33, Line 25, “and IFN γ mRNAs” should be changed to --and IFN- γ mRNAs--

Column 35, Line 9, “quantfication errors,” should be changed to --quantification errors,--

Column 35, Line 64, “in vitro incubaton” should be changed to --in vitro incubation--

Column 36, Line 25, “to monitor alloreactive” should be changed to --to monitor alloreactive--

Column 37, Line 14, “6FaM-” should be changed to --6Fam- --

Column 38, Lines 15-16, “dilution of PCR” should be changed to --dilutions of PCR--